{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T23:57:37Z","timestamp":1789516657618,"version":"build-2803163510"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T00:00:00Z","timestamp":1722556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T00:00:00Z","timestamp":1722556800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Applied Therapeutics, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"DOI":"10.1186\/s12933-024-02378-w","type":"journal-article","created":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T18:02:29Z","timestamp":1722621749000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Relationship between NT-proBNP, echocardiographic abnormalities and functional status in patients with subclinical siabetic cardiomyopathy"],"prefix":"10.1186","volume":"23","clinical-trial-number":[{"clinical-trial-number":"nct04083339","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Pishoy","family":"Gouda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javed","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Del Prato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasrien E.","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn S. P.","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Marwick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio","family":"Rosenstock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilson","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faiez","family":"Zannad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Januzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Ezekowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,2]]},"reference":[{"key":"2378_CR1","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.diabres.2017.03.024","volume":"128","author":"K Ogurtsova","year":"2017","unstructured":"Ogurtsova K, da Rocha Fernandes JD, Huang Y, Linnenkamp U, Guariguata L, Cho NH, et al. IDF diabetes atlas: global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Res Clin Pract. 2017;128:40\u201350. https:\/\/doi.org\/10.1016\/j.diabres.2017.03.024.","journal-title":"Diabetes Res Clin Pract"},{"issue":"6","key":"2378_CR2","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.jacc.2022.05.033","volume":"80","author":"R Mohebi","year":"2022","unstructured":"Mohebi R, Chen C, Ibrahim NE, McCarthy CP, Gaggin HK, Singer DE, et al. Cardiovascular disease projections in the United States based on the 2020 census estimates. J Am Coll Cardiol. 2022;80(6):565\u201378.","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"2378_CR3","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.2337\/dci22-0014","volume":"45","author":"R Pop-Busui","year":"2022","unstructured":"Pop-Busui R, Januzzi JL, Bruemmer D, Butalia S, Green JB, Horton WB, et al. Heart failure: an underappreciated complication of diabetes. A consensus report of the American Diabetes Association. Diabetes Care. 2022;45(7):1670\u201390.","journal-title":"Diabetes Care"},{"issue":"8","key":"2378_CR4","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.2337\/diacare.27.8.1879","volume":"27","author":"GA Nichols","year":"2004","unstructured":"Nichols GA, Gullion CM, Koro CE, Ephross SA, Brown JB. The incidence of congestive heart failure in type 2 diabetes: an update. Diabetes Care. 2004;27(8):1879\u201384.","journal-title":"Diabetes Care"},{"issue":"4","key":"2378_CR5","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.cardfail.2021.01.022","volume":"27","author":"B Bozkurt","year":"2021","unstructured":"Bozkurt B, Coats AJ, Tsutsui H, Abdelhamid M, Adamopoulos S, Albert N, et al. Universal definition and classification of heart failure: a report of the heart failure society of America, heart failure association of the European society of cardiology, Japanese heart failure society and writing committee of the universal definition of heart failure. J Card Fail. 2021;27(4):387\u2013413.","journal-title":"J Card Fail"},{"key":"2378_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11892-021-01407-2","volume":"21","author":"AM Stanton","year":"2021","unstructured":"Stanton AM, Vaduganathan M, Chang L-S, Turchin A, Januzzi JL, Aroda VR. Asymptomatic diabetic cardiomyopathy: an underrecognized entity in type 2 diabetes. Curr Diab Rep. 2021;21:1\u201311.","journal-title":"Curr Diab Rep"},{"issue":"3","key":"2378_CR7","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1093\/cvr\/cvab120","volume":"118","author":"QG Karwi","year":"2022","unstructured":"Karwi QG, Ho KL, Pherwani S, Ketema EB, Sun Q, Lopaschuk GD. Concurrent diabetes and heart failure: interplay and novel therapeutic approaches. Cardiovasc Res. 2022;118(3):686\u2013715. https:\/\/doi.org\/10.1093\/cvr\/cvab120.","journal-title":"Cardiovasc Res"},{"issue":"4","key":"2378_CR8","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.pcad.2019.03.003","volume":"62","author":"G Murtaza","year":"2019","unstructured":"Murtaza G, Virk HUH, Khalid M, Lavie CJ, Ventura H, Mukherjee D, et al. Diabetic cardiomyopathy-a comprehensive updated review. Prog Cardiovasc Dis. 2019;62(4):315\u201326.","journal-title":"Prog Cardiovasc Dis"},{"issue":"1","key":"2378_CR9","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1186\/s12933-022-01711-5","volume":"21","author":"A Halabi","year":"2022","unstructured":"Halabi A, Potter E, Yang H, Wright L, Sacre JW, Shaw JE, et al. Association of biomarkers and risk scores with subclinical left ventricular dysfunction in patients with type 2 diabetes mellitus. Cardiovasc Diabetol. 2022;21(1):278. https:\/\/doi.org\/10.1186\/s12933-022-01711-5.","journal-title":"Cardiovasc Diabetol"},{"issue":"4","key":"2378_CR10","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.jacc.2009.12.003","volume":"55","author":"M From Aaron","year":"2010","unstructured":"From Aaron M, Scott Christopher G, Chen Horng H. The development of heart failure in patients with diabetes mellitus and pre-clinical diastolic dysfunction. J Am Coll Cardiol. 2010;55(4):300\u20135. https:\/\/doi.org\/10.1016\/j.jacc.2009.12.003.","journal-title":"J Am Coll Cardiol"},{"issue":"19","key":"2378_CR11","doi-asserted-by":"publisher","first-page":"e017462","DOI":"10.1161\/JAHA.120.017462","volume":"9","author":"MVB Malachias","year":"2020","unstructured":"Malachias MVB, Jhund PS, Claggett BL, Wijkman MO, Bentley-Lewis R, Chaturvedi N, et al. NT\u2010proBNP by itself predicts death and cardiovascular events in high\u2010risk patients with type 2 diabetes mellitus. J Am Heart Assoc. 2020;9(19):e017462. https:\/\/doi.org\/10.1161\/JAHA.120.017462.","journal-title":"J Am Heart Assoc"},{"issue":"3","key":"2378_CR12","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.jchf.2020.10.013","volume":"9","author":"A Pandey","year":"2021","unstructured":"Pandey A, Vaduganathan M, Patel KV, Ayers C, Ballantyne CM, Kosiborod MN, et al. Biomarker-based risk prediction of incident heart failure in pre-diabetes and diabetes. JACC Heart Fail. 2021;9(3):215\u201323. https:\/\/doi.org\/10.1016\/j.jchf.2020.10.013.","journal-title":"JACC Heart Fail"},{"issue":"5","key":"2378_CR13","first-page":"723","volume":"7","author":"FP Brouwers","year":"2014","unstructured":"Brouwers FP, van Gilst WH, Damman K, van den Berg MP, Gansevoort RT, Bakker SJ, et al. Clinical risk stratification optimizes value of biomarkers to predict new-onset heart failure in a community-based cohort. Circulation: Heart Fail. 2014;7(5):723\u201331.","journal-title":"Circulation: Heart Fail"},{"issue":"8","key":"2378_CR14","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1016\/j.amjcard.2020.01.025","volume":"125","author":"K Nguyen","year":"2020","unstructured":"Nguyen K, Fan W, Bertoni A, Budoff MJ, Defilippi C, Lombardo D, et al. N-terminal pro B-type natriuretic peptide and high-sensitivity cardiac troponin as markers for heart failure and cardiovascular disease risks according to glucose status (from the multi-ethnic study of atherosclerosis [MESA]). Am J Cardiol. 2020;125(8):1194\u2013201.","journal-title":"Am J Cardiol"},{"issue":"4","key":"2378_CR15","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.jchf.2022.12.005","volume":"11","author":"X Jia","year":"2023","unstructured":"Jia X, Al Rifai M, Ndumele CE, Virani SS, de Lemos JA, Lee E, et al. Reclassification of Pre-heart failure stages using Cardiac biomarkers: the ARIC Study. JACC Heart Fail. 2023;11(4):440\u201350. https:\/\/doi.org\/10.1016\/j.jchf.2022.12.005. Epub 2023\/03\/08.","journal-title":"JACC Heart Fail"},{"key":"2378_CR16","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ahj.2022.11.003","volume":"256","author":"JL Januzzi Jr","year":"2023","unstructured":"Januzzi JL Jr, Butler J, Del Prato S, Ezekowitz JA, Ibrahim NE, Lam CS, et al. Rationale and design of the Aldose Reductase Inhibition for Stabilization of Exercise Capacity in Heart failure trial (ARISE-HF) in patients with high-risk diabetic cardiomyopathy. Am Heart J. 2023;256:25\u201336.","journal-title":"Am Heart J"},{"issue":"2","key":"2378_CR17","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.jacc.2024.03.380","volume":"84","author":"L Januzzi James","year":"2024","unstructured":"Januzzi James L, Butler J, Del Prato S, Ezekowitz Justin A, Ibrahim Nasrien E, Lam Carolyn SP, et al. Randomized trial of a selective aldose reductase inhibitor in patients with diabetic cardiomyopathy. J Am Coll Cardiol. 2024;84(2):137\u201348. https:\/\/doi.org\/10.1016\/j.jacc.2024.03.380.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"2378_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.echo.2018.06.004","volume":"32","author":"C Mitchell","year":"2019","unstructured":"Mitchell C, Rahko PS, Blauwet LA, Canaday B, Finstuen JA, Foster MC, et al. Guidelines for performing a comprehensive transthoracic echocardiographic examination in adults: recommendations from the American Society of Echocardiography. J Am Soc Echocardiogr. 2019;32(1):1\u201364.","journal-title":"J Am Soc Echocardiogr"},{"issue":"5","key":"2378_CR19","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/S0735-1097(00)00531-3","volume":"35","author":"CP Green","year":"2000","unstructured":"Green CP, Porter Charles B, Bresnahan Dennis R, Spertus John A. Development and evaluation of the Kansas City cardiomyopathy questionnaire: a new health status measure for heart failure. J Am Coll Cardiol. 2000;35(5):1245\u201355. https:\/\/doi.org\/10.1016\/S0735-1097(00)00531-3.","journal-title":"J Am Coll Cardiol"},{"key":"2378_CR20","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/0895-4356(93)90053-4","volume":"46","author":"RA Washburn","year":"1993","unstructured":"Washburn RA, Smith KW, Jette AM, Janney CA. The physical activity scale for the elderly (PASE): development and evaluation. J Clin Epidemiol. 1993;46:153\u201362. https:\/\/doi.org\/10.1016\/0895-4356(93)90053-4.","journal-title":"J Clin Epidemiol"},{"key":"2378_CR21","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.pcad.2023.05.002","volume":"79","author":"AM Yeung","year":"2023","unstructured":"Yeung AM, Huang J, Pandey A, Hashim IA, Kerr D, Pop-Busui R, et al. Biomarkers for the diagnosis of heart failure in people with diabetes: a consensus report from diabetes technology society. Prog Cardiovasc Dis. 2023;79:65\u201379.","journal-title":"Prog Cardiovasc Dis"},{"issue":"1","key":"2378_CR22","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.euje.2005.03.009","volume":"7","author":"R Valle","year":"2006","unstructured":"Valle R, Bagolin E, Canali C, Giovinazzo P, Barro S, Aspromonte N, et al. The BNP assay does not identify mild left ventricular diastolic dysfunction in asymptomatic diabetic patients. Eur J Echocardiography. 2006;7(1):40\u20134.","journal-title":"Eur J Echocardiography"},{"issue":"25","key":"2378_CR23","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1016\/j.jacc.2013.08.1622","volume":"62","author":"MK Poulsen","year":"2013","unstructured":"Poulsen MK, Dahl JS, Henriksen JE, Hey TM, H\u00f8ilund-Carlsen PF, Beck-Nielsen H, et al. Left atrial volume index: relation to long-term clinical outcome in type 2 diabetes. J Am Coll Cardiol. 2013;62(25):2416\u201321. https:\/\/doi.org\/10.1016\/j.jacc.2013.08.1622.","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"2378_CR24","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1016\/j.jcmg.2018.03.015","volume":"11","author":"Y Wang","year":"2018","unstructured":"Wang Y, Yang H, Huynh Q, Nolan M, Negishi K, Marwick Thomas H. Diagnosis of nonischemic stage B heart failure in type 2 diabetes mellitus. JACC: Cardiovasc Imaging. 2018;11(10):1390\u2013400. https:\/\/doi.org\/10.1016\/j.jcmg.2018.03.015.","journal-title":"JACC: Cardiovasc Imaging"},{"issue":"1","key":"2378_CR25","doi-asserted-by":"publisher","first-page":"37354","DOI":"10.1038\/srep37354","volume":"6","author":"D de Gonzalo-Calvo","year":"2016","unstructured":"de Gonzalo-Calvo D, Kenneweg F, Bang C, Toro R, van der Meer RW, Rijzewijk LJ, et al. Circulating long-non coding RNAs as biomarkers of left ventricular diastolic function and remodelling in patients with well-controlled type 2 diabetes. Sci Rep. 2016;6(1):37354. https:\/\/doi.org\/10.1038\/srep37354.","journal-title":"Sci Rep"},{"issue":"30","key":"2378_CR26","doi-asserted-by":"publisher","first-page":"e1218","DOI":"10.1097\/MD.0000000000001218","volume":"94","author":"L Gamella-Pozuelo","year":"2015","unstructured":"Gamella-Pozuelo L, Fuentes-Calvo I, G\u00f3mez-Marcos MA, Recio-Rodriguez JI, Agudo-Conde C, Fern\u00e1ndez-Mart\u00edn JL, et al. Plasma Cardiotrophin-1 as a marker of hypertension and diabetes-induced target organ damage and cardiovascular risk. Medicine. 2015;94(30):e1218.","journal-title":"Medicine."},{"issue":"3","key":"2378_CR27","doi-asserted-by":"publisher","first-page":"161","DOI":"10.7150\/ijms.14141","volume":"13","author":"A Shaver","year":"2016","unstructured":"Shaver A, Nichols A, Thompson E, Mallick A, Payne K, Jones C, et al. Role of serum biomarkers in early detection of diabetic cardiomyopathy in the West Virginian population. Int J Med Sci. 2016;13(3):161\u20138. https:\/\/doi.org\/10.7150\/ijms.14141.","journal-title":"Int J Med Sci"},{"issue":"1","key":"2378_CR28","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/1475-2840-12-150","volume":"12","author":"WJY Chen","year":"2013","unstructured":"Chen WJY, Greulich S, van der Meer RW, Rijzewijk LJ, Lamb HJ, de Roos A, et al. Activin a is associated with impaired myocardial glucose metabolism and left ventricular remodeling in patients with uncomplicated type 2 diabetes. Cardiovasc Diabetol. 2013;12(1):150. https:\/\/doi.org\/10.1186\/1475-2840-12-150.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"2378_CR29","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s12872-024-03810-5","volume":"24","author":"NR Iyer","year":"2024","unstructured":"Iyer NR, Chan S-P, Liew OW, Chong JPC, Bryant JA, Le T-T, et al. Global longitudinal strain and plasma biomarkers for prognosis in heart failure complicated by diabetes: a prospective observational study. BMC Cardiovasc Disord. 2024;24(1):141. https:\/\/doi.org\/10.1186\/s12872-024-03810-5.","journal-title":"BMC Cardiovasc Disord"},{"issue":"7","key":"2378_CR30","doi-asserted-by":"publisher","first-page":"e004451","DOI":"10.1161\/CIRCIMAGING.115.004451","volume":"9","author":"A Alashi","year":"2016","unstructured":"Alashi A, Mentias A, Patel K, Gillinov AM, Sabik JF, Popovi\u0107 ZB, et al. Synergistic utility of brain natriuretic peptide and left ventricular global longitudinal strain in asymptomatic patients with significant primary mitral regurgitation and preserved systolic function undergoing mitral valve surgery. Circ Cardiovasc Imaging. 2016;9(7):e004451. https:\/\/doi.org\/10.1161\/CIRCIMAGING.115.004451.","journal-title":"Circ Cardiovasc Imaging"},{"issue":"1","key":"2378_CR31","doi-asserted-by":"publisher","first-page":"e002561","DOI":"10.1161\/JAHA.115.002561","volume":"5","author":"A Goodman","year":"2016","unstructured":"Goodman A, Kusunose K, Popovic ZB, Parikh R, Barr T, Sabik JF, et al. Synergistic utility of brain natriuretic peptide and left ventricular strain in patients with significant aortic stenosis. J Am Heart Association. 2016;5(1):e002561. https:\/\/doi.org\/10.1161\/JAHA.115.002561.","journal-title":"J Am Heart Association"},{"issue":"3","key":"2378_CR32","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.jchf.2020.10.008","volume":"9","author":"KN Bachmann","year":"2021","unstructured":"Bachmann KN, Gupta DK, Xu M, Brittain E, Farber-Eger E, Arora P, et al. Unexpectedly low natriuretic peptide levels in patients with heart failure. JACC: Heart Fail. 2021;9(3):192\u2013200. https:\/\/doi.org\/10.1016\/j.jchf.2020.10.008.","journal-title":"JACC: Heart Fail"},{"issue":"10","key":"2378_CR33","doi-asserted-by":"publisher","first-page":"3242","DOI":"10.1210\/jc.2011-1182","volume":"96","author":"AM Khan","year":"2011","unstructured":"Khan AM, Cheng S, Magnusson M, Larson MG, Newton-Cheh C, McCabe EL, et al. Cardiac natriuretic peptides, obesity, and insulin resistance: evidence from two community-based studies. J Clin Endocrinol Metabolism. 2011;96(10):3242\u20139. https:\/\/doi.org\/10.1210\/jc.2011-1182.","journal-title":"J Clin Endocrinol Metabolism"},{"key":"2378_CR34","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.ijcard.2022.03.032","volume":"357","author":"A Avogaro","year":"2022","unstructured":"Avogaro A, Azzolina D, Gregori D, De Kreutzenberg S, Fadini GP, Mannucci E. The effect of GLP-1 receptor agonists on N-terminal pro-brain natriuretic peptide. A scoping review and metanalysis. Int J Cardiol. 2022;357:123\u20137. https:\/\/doi.org\/10.1016\/j.ijcard.2022.03.032. Epub 2022\/03\/21.","journal-title":"Int J Cardiol"},{"issue":"7","key":"2378_CR35","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.jchf.2015.02.008","volume":"3","author":"K Gupta Deepak","year":"2015","unstructured":"Gupta Deepak K, de Lemos James A, Ayers Colby R, Berry Jarett D, Wang Thomas J. Racial differences in natriuretic peptide levels. JACC: Heart Fail. 2015;3(7):513\u20139. https:\/\/doi.org\/10.1016\/j.jchf.2015.02.008.","journal-title":"JACC: Heart Fail"},{"key":"2378_CR36","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.ijcard.2019.02.034","volume":"286","author":"N Patel","year":"2019","unstructured":"Patel N, Guti\u00e9rrez OM, Arora G, Howard G, Howard VJ, Judd SE, et al. Race-based demographic, anthropometric and clinical correlates of N-terminal-pro B-type natriuretic peptide. Int J Cardiol. 2019;286:145\u201351. https:\/\/doi.org\/10.1016\/j.ijcard.2019.02.034.","journal-title":"Int J Cardiol"},{"issue":"9","key":"2378_CR37","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1016\/j.jacc.2019.06.055","volume":"74","author":"JL Januzzi Jr","year":"2019","unstructured":"Januzzi JL Jr., Ahmad T, Mulder H, Coles A, Anstrom KJ, Adams KF, et al. Natriuretic peptide response and outcomes in chronic heart failure with reduced ejection fraction. J Am Coll Cardiol. 2019;74(9):1205\u201317. https:\/\/doi.org\/10.1016\/j.jacc.2019.06.055. Epub 2019\/08\/31.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"2378_CR38","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1111\/chf.12016","volume":"19","author":"HK Gaggin","year":"2013","unstructured":"Gaggin HK, Truong QA, Rehman SU, Mohammed AA, Bhardwaj A, Parks KA, et al. Characterization and prediction of natriuretic peptide nonresponse during heart failure management: results from the Pro BNP outpatient tailored chronic heart failure (PROTECT) and the NT-pro BNP\u2013assisted treatment to lessen serial cardiac readmissions and death (BATTLESCARRED) study. Congestive Heart Fail. 2013;19(3):135\u201342.","journal-title":"Congestive Heart Fail"},{"issue":"9","key":"2378_CR39","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1093\/eurjhf\/hfq110","volume":"12","author":"S Kiencke","year":"2010","unstructured":"Kiencke S, Handschin R, von Dahlen R, Muser J, Brunner-Larocca HP, Schumann J, et al. Pre-clinical diabetic cardiomyopathy: prevalence, screening, and outcome. Eur J Heart Fail. 2010;12(9):951\u20137. https:\/\/doi.org\/10.1093\/eurjhf\/hfq110. Epub 2010\/06\/29.","journal-title":"Eur J Heart Fail"},{"issue":"8","key":"2378_CR40","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/j.hlc.2017.08.014","volume":"27","author":"MT Maeder","year":"2018","unstructured":"Maeder MT, Thompson BR, Kaye DM. Inverse Association between myocardial B-Type natriuretic peptide release and functional capacity in healthy humans. Heart. Lung Circulation. 2018;27(8):995\u20131003. https:\/\/doi.org\/10.1016\/j.hlc.2017.08.014.","journal-title":"Lung Circulation"},{"issue":"9","key":"2378_CR41","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1016\/j.rmed.2009.03.015","volume":"103","author":"MT Maeder","year":"2009","unstructured":"Maeder MT, Brutsche MH, Christ A, Reichlin T, Staub D, Noveanu M, et al. Natriuretic peptides for the prediction of severely impaired peak VO2 in patients with lung disease. Respir Med. 2009;103(9):1337\u201345. https:\/\/doi.org\/10.1016\/j.rmed.2009.03.015.","journal-title":"Respir Med"},{"issue":"4","key":"2378_CR42","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/S0735-1097(02)02032-6","volume":"40","author":"S Kr\u00fcger","year":"2002","unstructured":"Kr\u00fcger S, Graf J\u00fc, Kunz D, Stickel T, Hanrath P, Janssens U. Brain natriuretic peptide levels predict functional capacity in patients with chronic heart failure. J Am Coll Cardiol. 2002;40(4):718\u201322. https:\/\/doi.org\/10.1016\/S0735-1097(02)02032-6.","journal-title":"J Am Coll Cardiol"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-024-02378-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-024-02378-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-024-02378-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T18:03:46Z","timestamp":1722621826000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-024-02378-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,2]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2378"],"URL":"https:\/\/doi.org\/10.1186\/s12933-024-02378-w","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,2]]},"assertion":[{"value":"8 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Javed Butler: Consultant\u2014Abbott, American Regent, Amgen, Applied Therapeutic, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Cardiac Dimension, Cardior, CVRx, Cytokinetics, Edwards, Element Science, Innolife, Impulse Dynamics, Imbria, Inventiva, Lexicon, Lilly, LivaNova, Janssen, Medtronics, Merck, Occlutech, Novartis, Novo Nordisk, Pfizer, Pharmacosmos, Pharmain, Prolaio, Roche, Sequana, SQ Innovation, Tenex, and ViforWilson Tang: Dr. Tang served as consultant for Sequana Medical, Cardiol Therapeutics, Genomics plc, Zehna Therapeutics, Renovacor, WhiteSwell, Kiniksa, Boston Scientific, CardiaTec Biosciences, Intellia Therapeutics, and has received honorarium from Springer, Belvoir Media Group, and American Board of Internal Medicine. Carolyn S.P. Lam: Carolyn SP Lam is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore; has Received research support from NovoNordisk and Roche Diagnostics; has Served as consultant or on the Advisory Board\/ Steering Committee\/ Executive Committee for Alleviant Medical, Allysta Pharma, AnaCardio AB, Applied Therapeutics, AstraZeneca, Bayer, Biopeutics, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, CardioRenal, Cytokinetics, Darma Inc., EchoNous Inc, Eli Lilly, Impulse Dynamics, Intellia Therapeutics, Ionis Pharmaceutical, Janssen Research & Development LLC, Medscape\/WebMD Global LLC, Merck, Novartis, Novo Nordisk, Prosciento Inc, Quidel Corporation, Radcliffe Group Ltd., Recardio Inc, ReCor Medical, Roche Diagnostics, Sanofi, Siemens Healthcare Diagnostics and Us2.ai; and serves as co-founder & non-executive director of Us2.ai.Stefano Del Prato reports serving as president of EASD\/EFSD (2020-2022) and has received research grants to the institution from AstraZeneca and Boehringer Ingelheim; has served as advisor for Abbott, Applied Therapeutics, AstraZeneca, Boehringer Ingelheim, Eli Lilly & Co., EvaPharma, Jiangsu Hengrui Pharmaceuticals Co., Menarini International, Merck Sharpe & Dohme, Novartis Pharmaceutical Co., Novo Nordisk, Sanofi, Sun Pharmaceuticals; has received fees for speaking from Abbott, AstraZeneca, Berlin-Chemie, Boehringer Ingelheim, Eli Lilly & Co., Laboratori Guidotti, Menarini International, Merck Sharpe & Dohme, Novo Nordisk, Sanofi.All other authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"281"}}